Page results
-
Our mass vaccination centre at Bidborough House, which we have operated in partnership with UCL, closes on Friday 22 July.
-
Contrast Extravasation (contrast leakage) patient information leaflet
-
We are pleased to have performed very well again in this year's General Medical Council National Training Survey.
-
This page is for patients who have been referred by their GP to a gynaecology specialist because their symptoms need further tests.
-
Art and creativity can be a real tonic for health, says UCLH arts curator Guy Noble.
-
This page explains what a low-phosphate diet is. It also provides information about foods you can eat and foods to avoid when taking a medicine called futibatinib.
-
Taking blood pressure medication in the evening is no better than taking it in the morning, according to new research.
-
The iconic run has returned to its regular time of the year, following two years’ disruption following the pandemic and will take place on Sunday 2 October 2022. We are lucky enough to have five people running for UCLH Charity. The money they raise will help us support patients, staff and research at UCLH.
-
Information on contrast agents for X-ray, fluoroscopy, CT and angiography examinations at NHNN
-
UCLH continues to achieve excellent results in the National Inpatient Survey. In 2021 patients rated their overall care as 8.5 out of 10 which is the top score in London and the second best in the Shelford Group.
File results
-
FOI201769 A&E attendances by patients with mental health related issues
-
Charity Matters magazine - Winter 2020
-
FOI201771 Cataract and glaucoma operations
-
FOI201774 Maternity services
-
FOI201776 Serious incidents and deaths of patients with a learning disability
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0226 - Treatment with Nivolumab